0.14
-9.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About GeoVax Labs
From its filings with the US Securities and Exchange Commission
GeoVax Labs is based in Smyrna, Georgia and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GOVX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $2.5m and a net loss of $21.5m. At that date it held total assets of $6.3m and shareholders' equity of $3.8m.
GeoVax Labs, Inc. (“GeoVax”, “us”, “we” or the “Company”) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms.
GeoVax’s primary near-term strategic development priority is the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. GEO-MVA is being advanced on an expedited regulatory pathway in Europe and is intended to address a significant global supply constraint for orthopoxvirus vaccines. The Company believes GEO-MVA is well-positioned to support both civilian public health needs and broader preparedness and biodefense objectives. The advancement of GEO-MVA represents the Company’s most near-term opportunity to achieve regulatory approval and potential commercialization. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026.
The Company’s lead clinical program in oncology is Gedeptin®, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial evaluating Gedeptin® in combination with an immune checkpoint inhibitor (ICI) as first-line treatment of patients with squamous cell head and neck cancer eligible for curative surgery, is planned to initiate during the first half of 2027.
Quoted from its 10-K, filed 15 Apr 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Apr 1994
- Employees
- 19
- Website
- geovax.com ↗
- Head office
- 1955 LAKE PARK DRIVE, SMYRNA, GA
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. David DoddChairman of the Board, President, Chief Executive Officer, since 2010$645,795
- Mr. Mark ReynoldsChief Financial Officer, Corporate Secretary$421,400
- Dr. Mark NewmanChief Scientific Officer$456,540
- Dr. John SharkeyVice President - Business Development
- Dr. Kelly MckeeChief Medical Officer$534,969
- Dr. Randal ChaseIndependent Director$64,864
- Mr. Dean KollintzasIndependent Director$54,864
- Ms. Nicole LemerondIndependent Director$49,864
- Dr. Robert McNallyIndependent Director, since 2006$64,864
- Dr. Jayne MorganIndependent Director$47,364
- Mr. John SpencerIndependent Director$62,364
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- GeoVax Labs' MVA-VLP platform enables in vivo expression of non-infectious VLPs for vaccine development.
- The company focuses on HIV, Zika, and hemorrhagic fever viruses with a clinically advanced DNA/MVA regimen.
- GeoVax Labs' Tetravalent Vaccine targets future filovirus epidemics using its MVA-VLP platform.
Weaknesses
- GeoVax Labs has only 19 employees, which may limit research and development capacity.
- The company is a clinical-stage biotechnology firm with limited commercialization experience.
- GeoVax Labs' focus on specific diseases may restrict broader market opportunities.
Opportunities
- The growing demand for vaccines against emerging infectious diseases presents a significant opportunity.
- Expanding the MVA-VLP platform to new infectious diseases could increase market reach.
- Collaborations with global health organizations could accelerate vaccine development and distribution.
Threats
- Competition from established biotechnology firms in the Health Care sector poses a threat.
- Regulatory hurdles in vaccine development could delay product launches.
- Economic downturns might reduce funding for biotechnology research and development.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.